Clinical Trial

A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT

Recruiting
View on ClinicalTrials.gov →
Summary
Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.
Trial Details
NCT Number NCT07602569
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Cancer (With or Without Metastasis)
Enrollment 110 participants
Start Date 2025-10-20
Primary Completion 2028-08-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-22